SEC Form 4 · accession 0001140361-17-025877
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel D Burgess
Director
Period of report
Jun 21, 2017
Accepted (ET)
Jun 22, 2017 · 4:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001447028
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option Grant (Right to Buy) | $3.55 | Jun 21, 2017 | A | 22,000 | A | Jun 21, 2017 | Jun 21, 2027 | Common Shares | 22,000 | 22,000 | D |